A detailed history of Dempze Nancy E transactions in Abbott Laboratories stock. As of the latest transaction made, Dempze Nancy E holds 36,557 shares of ABT stock, worth $3.74 Million. This represents 3.58% of its overall portfolio holdings.

Number of Shares
36,557
Previous 35,725 2.33%
Holding current value
$3.74 Million
Previous $3.93 Million 5.67%
% of portfolio
3.58%
Previous 3.73%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$109.52 - $120.96 $91,120 - $100,638
832 Added 2.33%
36,557 $4.16 Million
Q4 2023

Feb 13, 2024

BUY
$90.19 - $110.4 $126,716 - $155,112
1,405 Added 4.09%
35,725 $3.93 Million
Q3 2023

Nov 14, 2023

BUY
$95.53 - $114.62 $66,584 - $79,890
697 Added 2.07%
34,320 $3.32 Million
Q2 2023

Aug 14, 2023

BUY
$100.78 - $112.29 $109,043 - $121,497
1,082 Added 3.33%
33,623 $3.67 Million
Q1 2023

May 10, 2023

BUY
$96.86 - $114.01 $58,794 - $69,204
607 Added 1.9%
32,541 $3.3 Million
Q4 2022

Feb 09, 2023

BUY
$95.06 - $111.52 $120,155 - $140,961
1,264 Added 4.12%
31,934 $3.51 Million
Q3 2022

Nov 08, 2022

BUY
$96.76 - $112.03 $193 - $224
2 Added 0.01%
30,670 $2.97 Million
Q2 2022

Jul 19, 2022

SELL
$102.07 - $123.37 $476,768 - $576,261
-4,671 Reduced 13.22%
30,668 $3.33 Million
Q1 2022

May 17, 2022

SELL
$114.02 - $139.04 $3,990 - $4,866
-35 Reduced 0.1%
35,339 $4.18 Million
Q4 2021

Feb 08, 2022

BUY
$115.53 - $141.46 $103,630 - $126,889
897 Added 2.6%
35,374 $4.98 Million
Q3 2021

Nov 10, 2021

SELL
$116.66 - $129.06 $9,332 - $10,324
-80 Reduced 0.23%
34,477 $4.07 Million
Q2 2021

Aug 09, 2021

SELL
$105.79 - $124.53 $400,415 - $471,346
-3,785 Reduced 9.87%
34,557 $4.01 Million
Q1 2021

May 17, 2021

SELL
$108.84 - $128.23 $124,077 - $146,182
-1,140 Reduced 2.89%
38,342 $4.6 Million
Q4 2020

Feb 16, 2021

SELL
$105.0 - $114.42 $138,075 - $150,462
-1,315 Reduced 3.22%
39,482 $4.32 Million
Q3 2020

Oct 28, 2020

BUY
$91.64 - $111.29 $224,518 - $272,660
2,450 Added 6.39%
40,797 $4.44 Million
Q2 2020

Jul 28, 2020

SELL
$76.57 - $98.0 $70,061 - $89,670
-915 Reduced 2.33%
38,347 $3.51 Million
Q1 2020

May 07, 2020

SELL
$62.82 - $91.86 $42,717 - $62,464
-680 Reduced 1.7%
39,262 $3.1 Million
Q4 2019

Jan 15, 2020

BUY
$78.51 - $87.4 $43,023 - $47,895
548 Added 1.39%
39,942 $3.47 Million
Q3 2019

Nov 07, 2019

SELL
$81.84 - $88.74 $363,451 - $394,094
-4,441 Reduced 10.13%
39,394 $3.3 Million
Q2 2019

Jul 24, 2019

SELL
$72.88 - $85.0 $89,350 - $104,210
-1,226 Reduced 2.72%
43,835 $3.69 Million
Q1 2019

May 01, 2019

SELL
$66.22 - $80.06 $36,685 - $44,353
-554 Reduced 1.21%
45,061 $3.6 Million
Q4 2018

Jan 24, 2019

SELL
$65.56 - $74.27 $116,893 - $132,423
-1,783 Reduced 3.76%
45,615 $3.3 Million
Q3 2018

Oct 15, 2018

SELL
$60.81 - $73.36 $1,581 - $1,907
-26 Reduced 0.05%
47,398 $3.48 Million
Q2 2018

Jul 30, 2018

SELL
$57.57 - $63.54 $25,273 - $27,894
-439 Reduced 0.92%
47,424 $2.89 Million
Q1 2018

Apr 24, 2018

BUY
$56.27 - $63.62 $19,525 - $22,076
347 Added 0.73%
47,863 $2.87 Million
Q4 2017

Feb 02, 2018

BUY
$53.68 - $57.47 $422,998 - $452,863
7,880 Added 19.88%
47,516 $2.71 Million
Q3 2017

Oct 26, 2017

BUY
$48.06 - $53.64 $1.9 Million - $2.13 Million
39,636
39,636 $2.12 Million

Others Institutions Holding ABT

About ABBOTT LABORATORIES


  • Ticker ABT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 1,751,219,968
  • Market Cap $179B
  • Description
  • Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for t...
More about ABT
Track This Portfolio

Track Dempze Nancy E Portfolio

Follow Dempze Nancy E and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dempze Nancy E, based on Form 13F filings with the SEC.

News

Stay updated on Dempze Nancy E with notifications on news.